Hypoalbuminaemia has been previously described to predict worse nonrelapse mortality (NRM) and inferior overall survival (OS) in allogeneic haematopoietic cell transplant (allo-HCT) recipients. Here, we evaluate the role of hypoalbuminaemia (<35 g/l) at time of onset of acute graft-versushost disease (aGVHD) when incorporated into the refined aGVHD score. The study population consisted of 522 patients, median age 53 (18-75) years, who underwent an allo-HCT mostly for haematological malignancies. Standard risk (SR) aGVHD comprised 467 patients (89%) and the number of high risk (HR) cases was 55 (11%). Median follow-up for all surviving patients was 26 (3-55) months. Two-year OS was significantly better in patients with SR aGVHD with a serum albumin ≥35 g/l compared to SR with albumin <35 g/l [70% (95% CI = 64-76%) vs. 49% (95% CI = 42-56%), P < 0Á0001]. Also, patients with SR aGVHD and a serum albumin level of ≥35 g/l had a significantly lower NRM at 1-year posttransplantation [6% (95% CI = 3-10%) vs. 25% (95% CI = 20-32%), P < 0Á0001]. After our findings are validated in a large cohort of patients, we propose that hypoalbuminaemia should be incorporated into the refined aGVHD risk score to further its ability to predict outcomes within this group.
Despite advances and availability of high resolution human leucocyte antigen (HLA) typing (Lee et al, 2007; Pidala et al, 2014) and the emergence of new regimens for immune suppression (Cutler et al, 2004; Pidala et al, 2015) , acute graftversus-host disease (aGVHD) remains a serious cause of morbidity and mortality in patients undergoing T-cell replete allogeneic haematopoietic cell transplantation (allo-HCT), representing a significant barrier to a higher success of the procedure (Mickelson et al, 2000; Flomenberg et al, 2004; Lee et al, 2007) . aGVHD is diagnosed based on the presence of clinical symptoms involving one or more organs, such as skin, liver and the gastrointestinal tract (Przepiorka et al, 1995) . Approximately 50% of aGVHD cases do not respond or become dependent on corticosteroids, which are the standard front-line treatment (Weisdorf et al, 1990; MacMillan et al, 2002) , and the prognosis of these patients is generally poor. A novel aGVHD risk score dichotomized aGVHD cases into two major prognostic groups: standard (SR) and high risk (HR) (MacMillan et al, 2012) , and this refined score has been validated in a larger multicentre study (MacMillan et al, 2015) .
Biomarkers for aGVHD are emerging and they may be incorporated into established grading systems to help identify patients at high(er) risk for aGVHD and eventually tailor treatment strategy based on predictive response (or lack thereof) to traditional therapies (Paczesny et al, 2010; Paczesny, 2013; Vander Lugt et al, 2013; Levine et al, 2015) . We and others have reported the prognostic significance of hypoalbuminaemia as a predictor of worse non-relapse mortality (NRM) and inferior overall survival (OS) in the setting research paper First published online 18 January 2018 doi: 10.1111/bjh.15105 of allo-HCT (Kharfan-Dabaja et al, 2011; Rezvani et al, 2011; Artz et al, 2016) .
Here, we evaluate the prognostic significance of hypoalbuminaemia at the time of onset of aGVHD when incorporated into the refined aGVHD score (MacMillan et al, 2012 (MacMillan et al, , 2015 .
Patients and methods
To be included, patients must have been ≥18 years of age at time of transplantation, but there was no predefined upper age limit. There were no exclusions based on diagnosis, remission status, cell source, donor source, regimen for aGVHD prophylaxis or dose-intensity of the preparative regimen. This study was approved by the institutional review board of the University of South Florida and was conducted in accordance with the Declaration of Helsinki. Hodgkin lymphoma (n = 6), T-cell prolymphocytic leukaemia (n = 4), myeloproliferative syndrome unspecified (n = 3), acute promyelocytic anaemia (n = 1), biphenotypic leukaemia (n = 1), paroxysmal nocturnal haemoglobinuria (n = 1), blastic plasmacytoid dendritic cell neoplasm (n = 1), acquired sideroblastic anaemia (n = 1), solid organ transplant-related aplasia (n = 1). †Derived from the request for information (RFI) Disease Classifications and Corresponding CIBMTR Classifications, ASBMT RFI 2017 (http://asbmt.org/practice-resources/rfi-forms) accessed on November 7, 2017.
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Study objectives, definition of endpoints, and statistical methodology
The primary objective of this study was to evaluate the prognostic significance of hypoalbuminaemia on OS when incorporated into the refined aGVHD score published by MacMillan et al (2012 MacMillan et al ( , 2015 . The secondary objective was to determine the effect of hypoalbuminaemia on NRM.
Patient-, disease-and procedure-related characteristics were summarized using descriptive statistics, such as median, standard deviation and range for continuous measures; and frequencies and proportion for categorical measures. OS was defined as time from onset of aGVHD to time of death from any cause and censored at the time of the last follow-up. Cumulative incidence of NRM was defined as time from day date of onset of aGVHD to death without evidence of relapse or progression and was calculated using Gray's competingrisks model (Gray, 1988) . aGVHD was graded according to 1994 consensus criteria (Przepiorka et al, 1995) and it was also classified according to the refined aGVHD score (MacMillan et al, 2012 (MacMillan et al, , 2015 . Intensity of the preparative regimen was defined according to Bacigalupo et al (2009) . Human leucocyte antigen (HLA)-match was defined as 8/8 (class I: A, B, C; class II: DRB1).
Probabilities of OS were calculated using the KaplanMeier estimate. Difference in OS curves was assessed using Log-rank test. A two-sided P-value of <0Á05 was the defined cut-off for statistical significance.
Univariate analyses for OS and NRM were performed by means of the Cox proportional hazards regression model. The final multivariable model was developed by allowing variables with P < 0Á10 to remain in the model, or adjusting for a priori-defined variable(s) known to potentially influence outcome.
The analysis of time-dependent receiver operating characteristics (ROC) curve was used to identify the serum albumin level (and date the level was obtained) that would show maximum specificity/sensitivity. Statistical analysis was performed using SPSS v22 (IBM Corp, Armonk, NY, USA) and NCSS 11 v.2016 (NCSS, LLC, Kaysville, UT, USA) statistical analysis software.
Results
We identified 681 consecutive patients who received an allo-HCT at the Moffitt Cancer Center between 1 January 2009 and 30 April 2013 for a variety of haematological malignancies or bone marrow (BM) failure syndromes. However, we excluded 159 (23%) patients who did not develop clinical evidence of aGVHD (n = 140) by day +100 post-transplantation or who had missing data on organ-specific aGVHD staging (n = 19). Our study sample consisted of 522 patients with a median age of 53 (18-75) years. HLA-matched unrelated donors (MUD) comprised the largest proportion of donors (n = 235, 45%). Filgrastim-mobilized peripheral blood stem cells (PBSC) was the predominant cell source (n = 479, 92%). The three most frequent diagnoses were acute myeloid leukaemia (AML) (n = 165, 32%), myelodysplastic syndrome (MDS) (n = 87, 17%) and acute lymphoblastic leukaemia (ALL) (n = 63, 12%). The distribution, based on disease risk according to criteria set forth by the Center for International Blood and Marrow Transplant Research (CIBMTR; http://asb mt.org/sites/default/files/asbmt_admin/ASBMT_RFI_2016_ CIBMTR_Diseas.pdf) was: low-risk = 35%, intermediaterisk = 24%, high-risk = 36% and unclassifiable = 5%. A methotrexate-based regimen was the most commonly prescribed GVHD prophylaxis (n = 259, 50%). These and other characteristics are summarized in Table I .
Acute GVHD grading
The median time to onset of aGVHD was 28 (7-98) days. As shown in Table II , the proportions of patients who developed aGVHD were: grade 1 (n = 95, 14%), grade 2 (n = 352, 53%), grade 3 (n = 69, 10%) and grade 4 (n = 6, 1%). When using the refined aGVHD score, the large majority of cases (n = 467, 89%) were considered SR and 55 (11%) were HR (Table II) .
ROC analysis to define serum albumin level cut-off point
In trying to define a significant and logical cut-off point for serum albumin group classification, several factors were taken into consideration. First, a normal serum albumin is generally between 35 and 50 g/l. Accordingly, any value below 35 g/l would be considered low or abnormal. More specific to this study, a cut-off of 35 g/l was also chosen after analysis of day +30 (post-transplant) serum albumin levels in this patient cohort. Day +30 was chosen as it fell within only 2 days of the median onset of aGVHD (28 days). The *GVHD: graft-versus-host disease, graded according to the 1994 consensus criteria (Przepiorka et al 1995) .
median serum albumin at day +30 for this cohort was 36 (15-48) g/l, making the cut-off of 35 g/l an even divider of the patient population. Additionally, ROC analysis of day +30 serum albumin levels showed maximum combined sensitivity and specificity in the range of 33-38 g/l.
Overall survival
Median follow-up for all surviving patients was 26 (3-55) months. The median follow-up for survivors who were classified as SR was 26 (3-55) months. For HR, the median follow-up of survivors was 36 (9-54) months. For SR patients, the median OS was not reached. For HR patients the median OS was 6 (95% CI = 2-10) months {hazard ratio = 2Á49 [95% confidence interval (CI) = 1Á75-3Á54], P < 0Á0001, Log-rank P < 0Á0001} (Table III) .
The 1-and 2-year OS for patients in the SR group was 70% (95% CI = 66-74%) and 61% (95% CI = 56-65%), respectively. The 1-and 2-year OS for patients in the HR group was 42% (95% CI = 29-55%) and 33% (95% CI = 20-46%), respectively (Fig 1) .
OS and serum albumin level. In SR patients, the median OS based on serum albumin level was as follows: albumin ≥35 g/l= median not reached vs. albumin <35 g/l = 23 (95% CI = 14-32) months, hazard ratio = 2Á09 (95% CI = 1Á55-2Á82), P < 0Á0001. The 2-year OS was significantly better in SR patients with a serum albumin ≥35 g/l compared to SR with albumin <35 g/l (70% (95% CI = 64-76%) vs. 49% (95% CI = 42-56%), P < 0Á0001) (Fig 2) . In patients with a refined HR aGVHD score, the median OS based on serum albumin level was as follows: albumin ≥35 g/ l = 14 (95% CI = 0-59) months vs. albumin <35 g/l = 5 (95% CI = 0-10) months, P = 0Á14. The overall hazard ratio for the HR group, based on serum albumin level, was 1Á75 (95% CI = 0Á80-3Á84); P = 0Á16. The 2-year OS was not significantly different in HR patients with serum albumin ≥35 g/l and HR with serum albumin <35 g/l [49% (95% CI = 22-76%) vs. 27% (95% CI = 13-41%)], P = 0Á12 (Fig 3) . 
Non-relapse mortality
The cumulative incidence of NRM at 6 months and 1 year for all patients was 13% (95% CI = 10-16%) and 18% (95% CI = 15-22%), respectively.
The NRM at 6 months was significantly higher in the HR group [42% (95% CI = 31-58%)] vs. the SR group [10% (95% CI = 7-13%)]. Differences were also observed at 1 year post-transplantation: HR group [47% (95% CI = 35-63%) vs. SR group 15% (95% CI = 12-18%), P < 0Á0001] (Fig 4) . NRM: SR group and serum albumin level. Patients with a refined SR aGVHD score and a serum albumin level of ≥35 g/l had a significantly lower NRM at 6 months [3% (95% CI = 2-6%) vs. 18% (95% CI = 13-24%)] and at 1 year [6% (95% CI = 3-10%) vs. 25% (95% CI = 20-32%)] post-transplantation, P < 0Á0001 (Fig 5) .
NRM: HR group and serum albumin level. Patients with a refined HR aGVHD score and a serum albumin level ≥35 g/l (vs. serum albumin < 35 g/l) had a lower NRM at 6 months [26% (95% CI = 10-69%) vs. 48% (95% CI = 35-67%)] -relapsed mortality by refined acute GVHD score (SR vs. HR). 95% CI, 95% confidence interval; GVHD, graft-versus-host disease; HR, high risk acute GVHD; NRM, non-relapse mortality; SR, standard risk acute GVHD.
Fig 5.
Non-relapsed mortality in standard risk acute GVHD and serum albumin. 95% CI, 95% confidence interval; GVHD, graft-versus-host disease; NRM, non-relapse mortality; SR, standard risk acute GVHD.
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and at 1 year [26% (95% CI = 10-69%) vs. 54% (95% CI = 40-73%)] post-transplantation, P = 0Á05 (Fig 6) .
Univariate and multivariable analysis
Overall survival. Table III summarizes the results of a univariate analysis assessing the prognostic significance of recipient age and gender, HCT comorbidity index score, serum albumin at date of aGVHD onset, aGVHD refined score (SR vs. HR), CIBMTR disease risk, intensity of the preparative regimen, donor source and cell source on OS.
Cox regression analysis, adjusted for age (as a continuous variable), showed that refined HR aGVHD score, serum albumin of <35 g/l at date of aGVHD onset and recipient male gender were independent predictors of inferior OS (Table IV) .
Non-relapse mortality. Table III summarizes the results of a univariate analysis assessing the prognostic significance of recipient age and gender, HCT comorbidity index score, serum albumin at date of aGVHD onset, aGVHD refined score (SR vs. HR), CIBMTR disease risk, intensity of the preparative regimen, donor source and cell source on NRM.
Cox regression analysis, adjusted for age (as a continuous variable) and HCT comorbidity index score, showed that refined HR aGVHD score and serum albumin of <35 g/l at date of aGVHD onset were independent predictors of worse NRM (Table V) . Non-relapsed mortality in high risk acute GVHD and serum albumin. 95% CI, 95% confidence interval; GVHD, graft-versus-host disease; HR, high risk acute GVHD; NRM, non-relapse mortality. Table IV . Multivariate analysis for overall survival (adjusted for age).
Variables
Hazard ratio (95% CI) P-value
Bold values denotes statistical significance. 95% CI, 95% confidence interval; aGVHD, acute graft-versus-host disease; HCT, haematopoietic cell transplantation; HR, high risk aGVHD; SR, standard risk aGVHD. 
Bold values denotes statistical significance. 95% CI, 95% confidence interval; aGVHD, acute graft-versus-host disease; BM, bone marrow; HCT, haematopoietic cell transplantation; HR, high risk aGVHD; MAC, myeloablative conditioning; MMD, mismatched donor; MRD, matched-related donor; MUD, matched unrelated donor; PBSC, granulocyte colony-stimulating factor mobilized peripheral blood stem cells; RIC/NMA, reduced intensity/non-myeloablative conditioning; SR, standard risk aGVHD; UCB, umbilical cord blood. *MMD includes mismatched related (N = 2) and mismatched unrelated (N = 86) donors. †Only six patients received BM as cell source.
Discussion
These results demonstrate the prognostic impact of hypoalbuminaemia on OS and NRM when incorporated into the refined aGVHD score created by MacMillan et al (2012 MacMillan et al ( , 2015 . In patients with a refined SR aGVHD score, presence of hypoalbuminaemia (<35 g/l) at the time of GVHD onset separated SR cases into two distinct prognostic subgroups with significantly different OS and NRM. This separation has important clinical implications in treatment outcomes and adds another risk stratification scheme to the established MacMillan aGVHD risk classification (MacMillan et al, 2012 (MacMillan et al, , 2015 . Our analysis suggests that those patients with refined SR aGVHD score with hypoalbuminaemia have inferior outcomes and, intuitively, these patients may benefit from more prompt and aggressive GVHD treatment(s), including enrolment in clinical trials to aim at improving their survival outlook. Cox regression analysis suggests that hypoalbuminaemia is an independent predictor of OS and NRM beyond the refined aGVHD score (Tables IV and V) .
Although a possible limitation of using albumin as a biomarker of severity of inflammation is the lack of organ-specific information, it is, however, a standardized test that is commonly used in clinical practice and it is also relatively inexpensive, hence providing a practical advantage from the application standpoint. The pathogenic relationship between hypoalbuminaemia and morbidity and/or death in the setting of allo-HCT and aGVHD remains to be better elucidated. However, the independent effect of albumin, apart from the refined aGVHD score on OS and NRM, suggests that hypoalbuminaemia may play a negative role beyond inflammation mediated by alloreactive T cells. It is plausible that, by adding established organspecific biomarkers (Paczesny et al, 2010; Harris et al, 2012) to this "refined aGVHD score plus hypoalbuminaemia model," its prognostic power may be improved and this may also help to tailor GVHD therapy accordingly. Furthermore, biomarkers could potentially help implement pre-emptive strategies for early intervention before aGVHD-mediated organ damage ensues; and it could also aid monitoring treatment response with the ultimate goal of personalizing care after allo-HCT through a better-informed risk-adapted approach.
In the case of the refined HR group, hypoalbuminaemia did not appear to affect 2-year OS in these patients (27% vs. 49%, P = 0Á12); but this finding may be limited by the small number of cases within this group. When assessing NRM, we observed a 2-fold higher risk of NRM in HR patients with hypoalbuminaemia at 1 year after allografting (54% vs. 26%, P = 0Á05). A larger multicentre collaborative study is needed to evaluate the effect of hypoalbuminaemia in patients with a refined HR aGVHD score.
Our findings could potentially influence practice change; however, we acknowledge that validation in a larger cohort of patients, preferably in the context of a multicentre collaborative study or using data from established haematopoietic cell transplantation registries, is certainly needed. After validation, we propose that hypoalbuminaemia should be incorporated into the refined aGVHD risk score (MacMillan et al, 2012 (MacMillan et al, , 2015 to further its ability to predict outcomes within the SR aGVHD group.
The presence of hypoalbuminaemia at the onset of aGVHD has prognostic implications and may help guide and optimize the treatment of aGVHD and eventually improve post-transplant outcomes.
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